Alps Advisors Inc. Makes New $346,000 Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

Alps Advisors Inc. purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,920 shares of the company's stock, valued at approximately $346,000.

A number of other hedge funds and other institutional investors have also modified their holdings of KRYS. Fifth Third Bancorp boosted its position in Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Krystal Biotech during the 4th quarter worth $95,000. Covestor Ltd boosted its holdings in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after purchasing an additional 642 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after purchasing an additional 432 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new position in Krystal Biotech in the first quarter valued at $223,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the sale, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. This represents a 0.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 49,800 shares of company stock worth $7,487,943. Insiders own 13.70% of the company's stock.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS traded down $2.66 during trading on Friday, reaching $147.49. 303,163 shares of the stock were exchanged, compared to its average volume of 287,380. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $219.34. The firm has a market cap of $4.26 billion, a price-to-earnings ratio of 35.45 and a beta of 0.67. The firm's 50-day moving average price is $136.27 and its 200 day moving average price is $156.00.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The business had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. As a group, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of research analyst reports. Guggenheim decreased their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, June 24th. Chardan Capital reissued a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research report on Wednesday, May 7th. Finally, Citigroup reaffirmed a "neutral" rating and set a $176.00 price target (up previously from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $213.75.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).